PAR's GENERIC VERSION OF MAXZIDE RECALLED JULY 24 DUE TO SAMPLE SWITCH DURING FDA INSPECTION; FIRM RECALLS THREE PRODUCTS REPRESENTING 6% OF SALES

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".